Eix Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Encourages Investors to Secure Their Seat in a Potential Class Action Lawsuit Against Eix

Bronstein Gewirtz & Grossman Files Class Action Lawsuit Against Edison International On April 15, 2025, Bronstein Gewirtz & Grossman, LLC, a prominent law firm, announced the filing of a class action lawsuit against Edison International (“Edison” or “the Company”) (NYSE:EIX) and certain of its officers. The lawsuit alleges that the Company and its executives violated…

Read More

Eguana Technologies Updates Progress on Exclusive 1-Megawatt British Columbia Feeder Program

Eguana Technologies Surpasses Half a Megawatt Mark in British Columbia Feeder Program Calgary, Alberta – The energy storage sector is witnessing significant growth, and Eguana Technologies Inc. (TSXV: EGT), a leading provider of high-performance energy storage systems, is at the forefront of this revolution. The company recently announced that its targeted feeder program, designed to…

Read More

Freightos Announces All-Time High in Transactions for Q1 2025: A New Milestone in Global Shipping

Freightos’ Q1 2025 Performance: A Beacon of Digital Transformation Resilience in Uncertain Tariff Waters Freightos Limited, a pioneering, vendor-neutral booking and payment platform for the international freight industry, recently announced its preliminary key performance indicators for the first quarter of 2025. The company reported a significant increase in transactions and gross booked volume (GBV), underscoring…

Read More

EU Investor Alert: Bronstein, Gewirtz and Grossman, LLC Announces Filing of a Tantalizing $100M Class Action Lawsuit

Bronstein, Gewirtz & Grossman, LLC: enCore Energy Corp. Faces Securities Class Action Lawsuit On April 15, 2025, Bronstein, Gewirtz & Grossman, LLC, a renowned law firm, took the initiative to notify investors about a class action lawsuit filed against enCore Energy Corp. (“enCore” or “the Company”) (NASDAQ:EU) and certain of its officers. The lawsuit alleges…

Read More

New Study Reveals Immunomodulatory and Anti-Fibrotic Potential of Caveolin-1 Peptide in IPF and PSC: Rein Therapeutics’ Latest Findings

Rein Therapeutics: Unraveling the Impact of LTI-2355 on Myeloid Cells in IPF and PASC-F Rein Therapeutics, a trailblazing biopharmaceutical company, recently published a groundbreaking study in the peer-reviewed journal, Biomedicines. The research, led by Rein, sheds light on the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID…

Read More